skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Review of teriflunomide and its potential in the treatment of multiple sclerosis

Review

(4723) Views  (1130) Full article downloads

Authors: Clemens Warnke, Gerd Meyer zu Hörste, Hans-Peter Hartung, Olaf Stüve, et al.

Published Date May 2009 Volume 2009:5 Pages 333 - 340
DOI: http://dx.doi.org/10.2147/NDT.S4474

Clemens Warnke1, Gerd Meyer zu Hörste1, Hans-Peter Hartung1, Olaf Stüve2,3,4, Bernd C Kieseier1

1Department of Neurology, Heinrich-Heine-University Düsseldorf, Germany; 2Neurology Section, VA North Texas Health Care System, Medical Service, Dallas, TX, USA; 3Department of Neurology; 4Department of immunology, University of Texas Southwestern Medical Center at Dallas, TX, USA

Abstract: In the light of new cases of progressive multifocal leukoencephalopathy and induced autoimmunity in multiple sclerosis (MS) patients who received treatment with upcoming disease-modifying immunosuppressant drugs with a highly specific mode of action such as natalizumab, rituximab, or alemtuzumab, alternative oral treatment options for a subgroup of less severely affected MS patients are a major focus of drug development. These agents are currently investigated in phase III clinical trials and some of them are characterized by a favorable safety profile. With an emphasis on teriflunomide, the active metabolite of an immunosuppressant approved for the treatment of rheumatoid arthritis since 1998, a number of oral treatment options for patients with MS are discussed.

Keywords: teriflunomide, multiple sclerosis, immunosuppressant, oral drugs






 

Other articles by Professor Bernd Kieseier



Readers of this article also read:

Natalizumab for the treatment of relapsing multiple sclerosis
Gamma knife radiosurgery for uveal melanoma ineligible for brachytherapy by the Collaborative Ocular Melanoma Study criteria
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Exacerbation rate, health status and mortality in COPD – a review of potential interventions
Information technology in pharmacovigilance: Benefits, challenges, and future directions from industry perspectives
Coenzyme Q10 effects in neurodegenerative disease
Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis
Identification of targets and new developments in the treatment of multiple sclerosis – focus on cladribine
New approaches in the management of multiple sclerosis
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy